

UC Berkeley

UC Berkeley Electronic Theses and Dissertations

Title

Hypersomnia in Bipolar Disorder: Clarifying a Diagnostic Dilemma

Permalink

<https://escholarship.org/uc/item/8tp200cm>

Author

Kaplan, Katherine Ann

Publication Date

2013

Peer reviewed|Thesis/dissertation

Hypersomnia in Bipolar Disorder: Clarifying a Diagnostic Dilemma

By

Katherine Ann Kaplan

A dissertation submitted in partial satisfaction of the

requirements for the degree of

Doctor of Philosophy

in

Psychology

in the

Graduate Division

of the

University of California, Berkeley

Committee in charge:

Professor Allison G. Harvey, Chair

Professor Matthew P. Walker

Professor Julianna Deardorff

Fall 2013

Abstract

Hypersomnia in Bipolar Disorder: Clarifying a Diagnostic Dilemma

by

Katherine Ann Kaplan

Doctor of Philosophy in Psychology

University of California, Berkeley

Professor Allison Harvey, Chair

Context: Hypersomnia is poorly defined, though evidence suggests it is associated with a range of negative health outcomes, poorer quality of life, and increased new-onset and recurrence of psychiatric illness. Lack of definition impedes generalizability across research studies.

Objective: To clarify hypersomnia diagnoses by exploring the possibility of subgroups, along with their relationship to prospective sleep data and relapse into psychiatric illness, in a sample of individuals with bipolar disorder.

Design: Prospective longitudinal analysis of a community psychiatric sample

Participants: The final sample included 159 adults (ages 18-70) with bipolar spectrum disorder diagnoses (I, II and NOS) who were euthymic at study entry.

Main Outcome Measures: Self-reports and clinician-administered interviews were used to determine features of hypersomnia, including habitual sleep duration, extent of excessive sleepiness, and napping. Participants completed sleep diaries and wore wrist actigraphy at home to obtain prospective sleep data in the home environment. Follow-up interviews were completed approximately seven months later and psychiatric status was assessed using the *Structured Clinical Interview for the DSM-IV (SCID)*.

Results: Factor analyses confirmed two separate subtypes of hypersomnia – a group characterized by long sleep time and a group characterized by excessive daytime sleepiness – that were uncorrelated ($r=-0.09$). Latent profile analyses suggested a four-class solution best characterized the data, with long sleep and excessive sleepiness representing two separate classes. Prospective sleep data suggested that the sleep of ‘long sleepers’ is characterized by long time in bed, not long sleep duration. Finally, longitudinal assessment of psychiatric illness suggested that excessive sleepiness at baseline predicted mania/hypomania relapse at follow-up.

Conclusions: This study is the largest investigation of hypersomnia to include objective measurement of sleep, and refines our understanding of classification, characterization and

associated morbidity. Hypersomnia appears to be comprised of two separate subgroups, long sleep and excessive sleepiness. Long sleep is characterized primarily by long bedrest duration. Excessive sleepiness is not associated with longer sleep or bedrest, but predicts relapse to mania/hypomania. Understanding these entities has important research and treatment implications.

Introduction

Evidence is accruing for the impact of hypersomnia on health, quality of life, and well-being across the lifespan. Adolescents with hypersomnia report more emotional disturbance, unhappiness and interpersonal problems,¹ adults with hypersomnia are 13.4 times more likely to abuse substances,² and older adults with excessive daytime sleepiness report significant impairment in daily activities and level of productivity.³ Individuals with hypersomnia are more likely to be taking medications, spending more on healthcare, and receiving government subsidies.⁴ A recent meta-analysis of 16 prospective studies documented that long habitual sleep was associated with increased rates of all-cause mortality, with long sleep conferring a 1.3x increased risk in the rate of subsequent death.⁵

Hypersomnia is a common feature of psychiatric disorders, especially the mood disorders, and portends poorer illness course. Hypersomnia is present in approximately 30% of individuals with major depressive disorder⁶ and is associated with longer, more severe and more treatment-resistant depressions.⁷ In unipolar depression, hypersomnia is one of the most treatment-resistant symptoms^{8,9} and a chief complaint of those not achieving remission from depression.¹⁰ Furthermore, prospective epidemiologic studies suggest that individuals with hypersomnia are 2.4 to 2.9 times more likely to develop a subsequent depressive episode one year later.^{2,11} In bipolar depression, hypersomnia is even more prevalent (estimated at 38-78% across studies)¹² and highly recurrent.¹³ Even outside of depressive episodes, roughly 25% of euthymic bipolar individuals experience hypersomnia, and this hypersomnia is associated with future depressive symptomatology.¹²

The present research focuses on hypersomnia in individuals with bipolar disorder for two primary reasons. First, among psychiatric disorders, hypersomnia appears to be most common in bipolar disorder.^{6,14-16} Second, hypersomnia persists into the inter-episode period of bipolar disorder at a relatively high rate.¹² Because reports of hypersomnia may be confounded with other symptoms of depression (e.g. anergia, avolition, psychomotor retardation)^{17,18} as well as mood-congruent biases in reporting, we chose to explore hypersomnia in an inter-episode sample. To our knowledge, this is the largest investigation of hypersomnia in a clinical sample using clinician-guided assessment and self-reports of hypersomnia along with subjective and objective measures of sleep.

Despite the evidence for the importance of hypersomnia in illness course and quality of life, problems related to definition and diagnosis abound.⁶ Diagnostic manuals, along with the empirical research they inform, appear divided in characterizing psychiatric hypersomnia by either long sleep duration or by excessive daytime sleepiness. For example, the DSM-IV-TR¹⁹ defines hypersomnia as “evidenced by either prolonged sleep episodes or daytime sleep episodes that occur almost daily,” and the DSM-V renames hypersomnia “hypersomnolence disorder,” and states that the disorder is characterized by “excessive sleepiness” evidenced by excessive need for sleep, long sleep, or excessive sleep inertia. A handful of studies echo the DSM-IV diagnosis in defining psychiatric hypersomnia via *long sleep*.^{1,20-23} By contrast, the International Classification of Diseases, Tenth Edition²⁴ and the International Classification of Sleep Disorders, Second Edition,²⁵ describe hypersomnia as *excessive sleepiness*, or the propensity of falling asleep during the daytime. Consistent with this definition, Ohayon et al²⁶ investigated excessive sleepiness in the general population, identifying self-reported excessive sleepiness symptoms most strongly associated with functional impairment. These researchers proposed a definition of ‘hypersomnia disorder’ characterized exclusively by excessive sleepiness, not long sleep.

Indeed, accruing evidence suggests that these two constructs—excessive sleepiness and long sleep—may not overlap. Ohayon²⁶ found no relationship between the frequency of

excessive sleepiness complaints and self-reported long sleep (though see Ohayon, 2013). Nofzinger et al²⁷ evaluated individuals diagnosed with bipolar disorder reporting hypersomnia (as defined by long sleep) on a daytime multiple sleep latency test, a measure of daytime sleepiness, and found no evidence for excessive sleepiness in this group. Additional studies have confirmed that excessive sleepiness, as measured objectively by daytime multiple sleep latency tests, is not present in individuals with psychiatric disorders who complain of long-sleep-defined hypersomnia.^{17,18,28} In sum, those who complain of long sleep at night do not demonstrate excessive sleepiness during the daytime, and there is a suggestion in the literature that long sleep and excessive sleepiness are uncorrelated. As such, one goal of the present paper is to examine if two separate groups are emerging under the umbrella term ‘hypersomnia’ – a group complaining of long sleep and a group complaining of excessive daytime sleepiness. At present, lack of an operational definition limits comparisons between studies and amalgamation of research findings. Correct classification of hypersomnia is essential to progress on understanding etiology, sequelae and treatment

At least two important such sequelae of hypersomnia are understudied. First, the relationship between self-reported hypersomnia and actual sleep obtained is unknown. Studies that have measured nighttime sleep objectively suggest that individuals with hypersomnia actually *sleep no longer* than their non-hypersomnic counterparts. For example, one continuous polysomnography protocol determined that a psychiatric hypersomnia group (N=36) slept only 7.68 hours on average, and only 14% slept beyond nine hours.¹⁷ This finding has subsequently been replicated by multiple groups using polysomnography, actigraphy and sleep diary.^{12,18,27,28} Individuals with insomnia have long been known to overestimate wakefulness and underestimate total sleep time, suggesting misperception of sleep states.^{29,30} It is unclear if individuals with hypersomnia similarly misperceive their sleep,^{31,32} though this has clear implications for understanding etiology and treatment. Second, as noted above, studies have established that hypersomnia confers increased likelihood of developing psychiatric illness.^{2,11} The extent to which excessive sleepiness, as compared to long sleep, differentially impacts rates of relapse into illness episodes is not known.

This paper addresses diagnostic confusion and understudied consequences by contributing data relating to hypersomnia classification and sequelae in a relatively large clinical sample. The goal is to identify subtypes of hypersomnia—namely, self-reported long sleep and excessive sleepiness—and to examine the relationship of these subtypes to prospective sleep data and relapse into depression and/or mania. We use a data-driven approach to delineating subtypes of hypersomnia based on a multi-method combination of subjective, objective and clinician-guided instruments. The first aim was to evaluate the independence of self-reported long sleep and self-reported excessive sleepiness^{6,17} via confirmatory factor analysis and latent profile analysis, controlling for the effects of psychotropic medications. The second aim was to investigate the relationship between hypersomnia subtype, prospective sleep data, and episode relapse to better characterize the sleep and psychiatric morbidity of individuals who complain of hypersomnia.

Methods

Sample

The present data is a secondary analysis of data accrued from three separate studies on sleep in bipolar disorder conducted between December 2005 and November 2011. Adult participants over age 18 were recruited from advertisements, online bulletins and physician referrals. The final sample included 159 adults (ages 18-70) with bipolar spectrum disorder diagnoses (I, II and NOS) who were inter-episode at study entry. Care was taken to ensure

that participants were recruited to reflect Alameda County demographics. A summary of participant characteristics is presented in Table 1.

[Insert Table 1 About Here]

Individuals from all studies were eligible to participate if they (a) met DSM-IV criteria for a diagnosis of bipolar disorder type I, II, or NOS, as determined by the Structured Clinical Interview for the DSM-IV (SCID; Spitzer et al., 1995); (b) did not meet criteria for a diagnosis of current substance or alcohol abuse or dependence; (c) did not meet criteria for narcolepsy, sleep apnea, restless leg syndrome or periodic limb movement disorder based on the Duke Structured Interview for Sleep Disorders (DSISD;³³ and (d) did not report history of severe head trauma, stroke, neurological disease, or severe medical illness (e.g., advanced autoimmune disorder). Inter-episode status was confirmed with the SCID and established cutoff scores on the Inventory of Depressive Symptomatology, Clinician Version (IDS-C)³⁴ and the Young Mania Rating Scale (YMRS).³⁵ All participants were required to be under the care of a psychiatrist, and information on medication dose and administration was collected upon study entry. Participants were not excluded on the basis of comorbidities or pharmacological treatments, given that comorbidity and polytherapy are common features of bipolar disorder. As medication class and dosing may influence the course and associated features of hypersomnia, however, medication effects were examined using an approach developed by Phillips et al.^{36,37} that considers both the number and dose of psychotropic medications in evaluating their impact.

Diagnostic Measures

The SCID;³⁸ is a semi-structured interview designed to assess DSM-IV diagnostic criteria for Axis I disorders. The SCID has good inter-rater reliability for a majority of psychiatric disorders.^{39,40} Trained doctoral students and postdoctoral fellows in clinical psychology administered the SCID to all participants to assess current and lifetime Axis I disorders. Diagnostic inter-rater reliability was established by re-scoring a randomly-selected sample of SCID interviews ($n=35$); diagnoses matched those made by the original interviewer in all cases ($k=1.00$). The DSISD;³³ is a semi-structured interview that assesses research diagnostic criteria for sleep disorders. The DSISD has been shown to have acceptable reliability and validity.⁴¹

Inter-episode status was confirmed using established cutoffs on the IDS-C and the YMRS. The IDS-C³⁴ is a 30-item clinician-guided instrument used to assess severity of depressive symptoms. The measure has demonstrated good reliability and validity.⁴² The YMRS⁴³ is an 11-item measure used to assess the severity of manic symptoms, also shown to have good reliability and validity.⁴³

Hypersomnia Indicators

The IDS-C³⁴ contains an item designed to assess the presence of hypersomnia based on self-reported sleep length in the past month. This item requires clinicians to probe for typical and maximal sleep length in a 24-hour period, including prompts for napping. The IDS-C classifies its symptom levels according to number of hours slept over a 24-hour period. It has previously been shown to have utility in assessing bipolar hypersomnia.^{12,44} Inter-rater reliability for this item, established using intra-class correlations⁴⁵ between the original item score and a randomly-selected sample of IDS-C interviews ($n=30$), was found to be excellent ($r=0.97$).

The Inventory of Depressive Symptomatology, Self Report (IDS-SR)³⁴ mirrors the content of the IDS-C in a self-report format. The hypersomnia item of the IDS-SR asks participants to rate the longest period slept in a 24-hour period over the past week, including naps.

The Pittsburgh Sleep Quality Index (PSQI)⁴⁶ is a 19-item self-report measure of subjective sleep quality in the last month yielding a global score and seven component scores. Two items from the PSQI were chosen as indicators of hypersomnia. The first was an item assessing self-reported sleep duration in the past month. The second indicator was the Daytime Dysfunction subscale, derived from two questions about excessive sleepiness and daytime impairment. The PSQI has been shown to have good internal consistency and test-retest reliability.⁴⁷

The Epworth Sleepiness Scale (ESS)⁴⁸ is a self-report measure of excessive daytime sleepiness. This questionnaire assesses the likelihood of falling asleep in 8 different situations, yielding a composite score of sleepiness severity. The ESS has shown good internal consistency and high test-retest reliability.⁴⁹

Finally, to more directly tap the construct of excessive sleepiness, individuals were queried about the severity of their daytime sleepiness. Mirroring the definition seen in the ICSD-2 and ICD-10, participants were queried “To what extent do you think that you feel sleepy during the daytime?” and asked to rate their response on a 5-point Likert-type scale, ranging from “not at all” to “very much.” This item is subsequently referred to as the “Excessive Sleepiness Item.”

Prospective Sleep Data.

All participants kept standard sleep diaries for one week to assess parameters including total sleep time, time in bed and sleep efficiency. The sleep diary has been shown to be a reliable estimate^{50,51} and is considered the gold standard subjective measure of sleep.^{52,53} Participants completed the log prior to sleep and upon waking, and a subset of participants (N=91) were required to call a voicemail twice daily with their answers to ensure compliance. Total sleep time was calculated by subtracting all time spent awake from all time spent in bed over a 24 hour period. Time in bed was scored by summing all intended sleep periods, excluding periods of reading or television watching in bed.

A subset of participants (N=75) were also equipped with an actigraph (Actiwatch AW-64; Mini Mitter, Philips Respironics Inc., Bend OR) to obtain an objective estimate of sleep for up to four weeks. Actigraphs are small wrist watch-like devices that provide an empirical estimate of the sleep/wake cycle via movement. Movement data are recorded for up to several weeks at a time, then downloaded onto a computer and analyzed to generate various sleep parameters. Actigraphy has been used in previous research focusing on sleep parameters in bipolar disorder⁵⁴⁻⁵⁷ and has recently been validated as a reliable measure for sleep length and fragmentation in a bipolar sample.⁵⁸ This device features a sensitivity of 0.05g and a bandwidth between 3 Hz and 11 Hz, with a sampling frequency of 32 Hz. Analyses were completed using the medium sensitivity setting and immobile minutes algorithm in Actiware 5.57. Mirroring the variables extracted from sleep diaries, total daily sleep time and time in bed were extracted from actigraph output.

Procedures

All procedures were approved by the University of California, Berkeley, Committee for the Protection of Human Subjects. After completing the initial telephone screen, participants who appeared likely to be eligible were invited to the laboratory for a baseline visit. During this visit participants signed informed consent and were interviewed by trained postdoctoral or doctoral researchers to assess the diagnostic status and symptom severity using the SCID, the DSISD, the YMRS, and the IDS-C. Once eligibility was determined by these measures, participants completed the remaining self-report and clinician-guided indicators of hypersomnia. All eligible participants completed the daily sleep diary and wore the actiwatch for one week. Approximately seven months after this initial visit (222 ± 73

days), participants were invited to the laboratory or contacted via telephone and a trained interviewer re-assessed psychiatric diagnoses over the seven-month period via the SCID. The present analyses examined relapse into mania, hypomania or depression within this seven-month follow-up time period.

Data Analyses.

Confirmatory factor analysis (CFA) was conducted using Amos 20.0 (IBM SPSS, Inc.) to test the *a priori* hypothesis that hypersomnia is composed of two distinct subtypes, long sleep and excessive daytime sleepiness. Following generally-accepted guidelines, sample size to number of indicators was kept above 20 to ensure stability of the model.^{59,60} Model fit was evaluated using established standards, including chi-square to degrees of freedom ratio (χ^2/df) ≤ 3 , comparative fit indices (CFI) and Tucker-Lewis indices (TLI) > 0.85 , and the root mean square error of approximation (RMSEA) < 0.05 .^{61,62} Missing data was imputed using the imbedded Full Information Maximum Likelihood algorithm, though structural integrity of all models was confirmed by comparing the imputed model to a complete model where missing data were deleted list-wise. Likewise, to evaluate the impact of bipolar spectrum diagnosis (i.e. I, II or NOS) on model stability, model fit for the full sample was compared to a model with Bipolar II and Bipolar NOS ($n=16$) omitted from analyses. Model fit for a two-factor solution was evaluated against a more parsimonious one-factor model by examining the statistical significance (i.e., p value) associated with the $\Delta\chi^2/df$ value.⁶³

Latent profile analysis (LPA) was used to determine the number and composition of groups into which participants are placed based on maximum likelihood estimation.⁶⁴ LPA is a type of cluster analysis that seeks to establish group membership in categorical latent variables (hypersomnia subtypes) using continuous manifest indicators (sleep reports). Unlike traditional cluster analysis, latent profile analysis establishes group membership by probability score, not distance, and is not subject to the same constraints as traditional cluster analyses.⁶⁵ LPA was conducted using Mplus 6.11⁶⁶ with the number of latent classes determined by the Bayesian information criteria parsimony index⁶⁷, the interpretability of clusters, the Lo-Mendell-Rubin adjusted likelihood-ratio test⁶⁸ and the Bootstrap likelihood-ratio test⁶⁹ between the estimated model and a model with one less class.

In order to evaluate the association between hypersomnia subtypes and prospective sleep data, we applied a structural equation modeling (SEM) framework to our latent factors, looking for relations between subtype membership and sleep variables (total sleep time and time in bed) using the standard indices of model fit described above. In a similar fashion, SEM was used to evaluate the relationship between hypersomnia subgroup and relapse into depression or mania at follow up. As relapse was a binary variable, Markov chain Monte Carlo methods were used in these path analyses. Correlations among exogenous variables were examined before restricting covariances to zero.

Medication Analyses. To evaluate the potential effect of psychotropic medication on hypersomnia class membership, medication load score^{12,36,70} was then included as a covariate in our CFA models and our LPA analyses. Medication load scores, designed to account for both the number and dose of psychotropic medications present, involve classifying each medication as 'low' or 'high' and assigning a corresponding score of 1 or 2 based on published parameters for antidepressants and mood stabilizers⁷¹ and for chlorpromazine-equivalent mean effective daily doses (ED₅₀) of antipsychotics.⁷² Anxiolytics and hypnotics are coded 1 or 2 based on midpoint of dose range as recommended in the *Physician's Desk Reference*.⁷³ A composite measure of medication load is created for each participant by

summing across medication codes and classes, reflecting both dose and diversity of medications taken by each participant.³⁶

Results

Factor Analyses. The factor loadings from the two-factor model evaluated are presented in Table 2. The overall fit of the model was good ($\chi^2/df=1.48$, $df=8$, $p=0.16$, CFI=0.97, TLI=0.92, RMSEA=0.05). As expected, all factor loadings onto the ‘long sleep’ and ‘excessive sleepiness’ factors were significant (mean loading=0.66). Furthermore, the two factors themselves were uncorrelated ($r=-0.09$), suggesting independence. Finally, the two-factor model provided a superior fit to the data than a more parsimonious one-factor model ($\Delta\chi^2=37.04$, $df=2$, $p<0.0001$).

[Insert Table 2 About Here]

To evaluate the influence of bipolar spectrum diagnosis on the model, individuals without Bipolar I Disorder (i.e. Bipolar II and NOS; $n=16$) were excluded. The fit of the model remained acceptable even after deleting these participants ($\chi^2/df=0.94$, $df=8$, $p=0.48$, CFI=1.0, TLI=1.01, RMSEA = 0.00). Likewise, the overall fit of the model was largely satisfactory⁷⁴ after deleting missing data list-wise ($\chi^2/df=2.07$, $df=8$, $p=0.04$, CFI=0.90, TLI=0.80, RMSEA = 0.14). Thus, confirmatory factor analysis suggested that ‘long sleep’ and ‘excessive sleepiness’ were separate and uncorrelated latent factors, and that this superior two-factor solution held even after excluding bipolar spectrum disorders and missing data.

Latent Profile Analyses. Comparison of BIC values from two- (BIC=3531.87), three- (BIC=3318.98), four- (BIC=3296.88) and five- (BIC=3303.34) class LPA models provided evidence for the four-class model’s superior relative fit. Class 1 ($n=16$, ‘Long Sleep’) consisted of individuals with long sleep duration and a relative absence of excessive sleepiness complaints. These individuals reported sleeping over 9 hours on average per night and feeling “a little” to “somewhat” sleepy during the daytime, with ESS scores in a non-clinical (<10) range. Class 2 ($n=15$, ‘Excessive Sleepiness’) consisted of individuals reporting clinically-significant ESS scores and rating daytime sleepiness between “a lot” and “very much.” Class 3 ($n=88$, ‘Short Sleep’) and Class 4 ($n=39$, ‘Normal Sleep’) was comprised of individuals who did not report excessive sleepiness (ESS scores <10) but self-reported an average sleep duration of 6.4 hours and 8.2 hours, respectively. Table 2 presents response probabilities of each hypersomnia indicator according to latent class membership. In sum, latent profile analyses again suggested that ‘long sleep’ and ‘excessive sleepiness’ were best defined as separate classes.

To examine whether bipolar spectrum diagnosis or missing data imputation affected model fit, separate latent class analyses were run excluding non-Bipolar I participants and excluding missing data list-wise. A four class solution continued to illustrate superior fit when excluding Bipolar II and NOS subjects from analyses (BIC for 2, 3, 4, and 5 class solutions were 3234.70, 3016.47, 3006.82, and 3008.66, respectively) and when excluding missing data list-wise (BIC for 2, 3, 4, and 5 class solutions were 1599.30, 1578.24, 1543.88, and 1556.39, respectively).

Medication Analyses. A summary of psychotropic medications taken by the participants in the sample is presented in Table 1. Participants took an average of 2.5 ± 1.5 medications. Mean medication load score for all participants taking medications was 3.4 ± 2.1 . When entered as a covariate in our CFA models, medication load score did not significantly improve model fit ($\Delta\chi^2=39.01$, $df=2$, $p<0.0001$). Likewise, there was no difference in medication load scores between the ‘Long Sleep’ class (4.2 ± 2.5) and the ‘Excessive Sleepiness’ class (3.9 ± 2.0) as determined by LPA analyses ($t(27)=0.4$, $p=0.69$). Thus,

medications did not appear to influence confirmatory factor analyses and did not differ between the ‘Long Sleep’ and ‘Excessive Sleepiness’ classes.

Relationship to Prospective Sleep Data. We evaluated the relationship between hypersomnia subtype and prospective sleep data (average total sleep time and average time in bed) for both sleep diary and actigraphy within an SEM framework. Considering sleep diary data first, we found acceptable model fit ($\chi^2/df=1.12$, CFI=0.99, TLI=0.98, RMSEA=0.03) for average total sleep time with significant factor loading onto ‘long sleep’ ($p<0.001$) but with nonsignificant loading onto ‘excessive sleepiness’ ($p=0.75$). Likewise, acceptable model fit ($\chi^2/df=2.0$, CFI=0.98, TLI=0.97, RMSEA=0.04) was observed for average time in bed with significant factor loading onto ‘long sleep’ ($p<0.001$) but with nonsignificant loading onto ‘excessive sleepiness’ ($p=0.73$). In contrast, actigraphy data for average total sleep time revealed acceptable model fit ($\chi^2/df=1.12$, CFI=0.99, TLI=0.98, RMSEA=0.03) but no significant factor loadings onto either ‘long sleep’ ($p=0.22$) or ‘excessive sleepiness’ ($p=0.08$). Actigraphy time in bed analyses showed acceptable model fit ($\chi^2/df=1.45$, CFI=0.96, TLI=0.90, RMSEA=0.05) with a significant factor loading onto ‘long sleep’ ($p=0.05$) but with nonsignificant loading onto ‘excessive sleepiness’ ($p=0.15$). In summary, sleep diary data suggested that ‘long sleep’, but not ‘excessive sleepiness’, was related to total sleep time and time in bed. Actigraphy further suggested ‘long sleep’ was characterized by time in bed, not total sleep time.

Relationship to Illness Relapse. The relationship between hypersomnia subtype and bipolar relapse was also investigated. Considering relapse to depression within the seven-month evaluation period, neither ‘long sleep’ nor ‘excessive sleepiness’ predicted relapse into depression ($p>0.05$ for both). In examining relapse into mania, ‘excessive sleepiness’ predicted relapse into mania ($p<0.01$) while ‘long sleep’ was not a significant predictor of manic relapse ($p=0.78$).

Comment

To our knowledge, this is the largest study of hypersomnia in a clinical sample using clinician-administered and self-reports of hypersomnia, as well as the largest to evaluate hypersomnia using subjective and objective measures of sleep. This paper makes four important contributions to our understanding of hypersomnia. First, we found that hypersomnia is comprised of two separate subgroups, ‘long sleep’ and ‘excessive sleepiness’. Second, neither of these subgroups appears differentially impacted by medications. Third, the objective sleep of ‘long sleepers’ is characterized by long time in bed, not long sleep duration. Forth, excessive sleepiness predicts relapse to mania.

Our data clearly suggest evidence for subtypes of hypersomnia. Factor analyses point to long sleep and excessive sleepiness as separate constructs. Likewise, latent profile analyses, which are considered an appropriate method for identifying symptom structure when no ‘gold-standard’ diagnosis is available,⁷⁵ also identified long sleep and excessive sleepiness as belonging to separate classes. Though this has been suggested in the literature,^{17,26,27} our investigation was the first to provide empirical data indicating that long sleep and excessive sleepiness are indeed separate and uncorrelated. It should be noted that this finding stands in contrast to a recent population-based telephone survey,⁷⁶ in which a positive correlation was noted between sleep length and excessive sleepiness. Differences in studies are likely to be accounted for by differences in sampling, methodology, and participants. This telephone-based investigation did not focus on a clinical sample, relied exclusively on self-report, and did not exclude participants based on presence of sleep disorders such as obstructive sleep apnea or periodic limb movement disorder. As these

sleep disorders involve disrupted sleep continuity, individuals are likely to experience *both* excessive sleepiness (from insufficient nocturnal sleep) and long sleep (reflecting a homeostatic compensatory process). The present investigation offered a clearer picture of hypersomnia by excluding such confounding sleep disorders. It further utilized clinician interviews along with self-report to make hypersomnia determinations, thereby addressing a finding in the literature that individuals with hypersomnia overestimate their sleep^{31,32} when asked to estimate via self-report alone.

Neither long sleep nor excessive sleepiness appeared to be differentially influenced by medications. The number and dose of medications taken by those classified as having 'long sleep' or 'excessive daytime sleepiness' were not significantly different, and medications were not a significant covariate in our models. Even so, medications present a challenge in research with clinical samples. Sleep-related side effects are present in 4% to 37% of patients with bipolar disorder,^{77,78} and atypical antipsychotics in particular are known for their sedative properties.⁷⁹ As research in medication-free bipolar samples is neither representative nor generalizable, we did not exclude on the basis of medications and instead assessed effects of medications in careful post-hoc analyses. We did not control for medication changes over the seven-month interval between baseline evaluation and follow-up. Hence, a limitation is that medication changes during this period may have influenced rates of relapse. Even so, medications remain the first line treatment of bipolar disorder⁸⁰ and dose changes and medication augmentations are quite common in the course of treatment.

Viewing hypersomnia as comprised of subtypes has important implications for researching etiology and understanding mechanisms. Long sleep has multiple proposed etiologies, including both biological (decreased slow wave activity at night,⁴⁴ a slower circadian pacemaker⁸¹), and psychological (anergia or avolition,^{17,27} avoidance coping⁸²) mechanisms. Likewise recent research suggests that excessive sleepiness may be related to decreased cerebrospinal fluid histamine levels⁸³ and differences in the human leukocyte antigen (HLA) DQB1*0602.⁸⁴ The degree to which these proposed mechanisms might overlap—or differentiate—long sleep from excessive sleepiness is still unknown. Treatment of long sleep and excessive sleepiness is also likely to be quite different based on understanding of these mechanisms.

One key finding emerged from prospective sleep measurement: actigraphy data collected over a 24-hour period suggested that long sleepers displayed longer time in bed but *not* longer total sleep time. In other words, the sleep of self-reported long sleepers is characterized by excessive bedrest duration. This finding has been observed in studies utilizing polysomnography^{12,18,27,28} but has not been examined in the home environment using actigraphy. A relatively recent publication by the American Academy of Sleep Medicine on practice parameters for actigraphy commented on the lack of studies employing actigraphy in hypersomnia, noting that “there were no studies identified that compared actigraphy versus the clinical history plus sleep logs (or another reference standard) to estimate mean sleep time or sleep pattern when evaluating patients with hypersomnia as a complaint.”⁸⁵ The present study is the first to use actigraphy expressly to evaluate sleep in hypersomnia and provides evidence for its utility in characterizing the sleep disturbance. It should also be noted that excessive sleepiness was not associated with increased total sleep time or time in bed in either diaries or actigraphy, adding further support for long sleep and excessive sleepiness as separate subtypes of hypersomnia.

Multiple studies suggest that sleep disturbances such as hypersomnia predict first episode and recurrence of depression.^{2,11,86} Surprisingly, our findings did not support this relationship, as we observed neither long sleep nor excessive sleepiness predicted relapse to a

depression at 7-month follow-up. We offer two possible explanations as to why this may be the case. First, our follow-up period was seven months, whereas other prospective research on hypersomnia and depression had follow-up durations of anywhere from one to three years; as such, had the interval between baseline and follow-up assessment been longer, a positive relationship might have emerged. Second, we defined relapse as a SCID-assessed depressive episode, though it may be the case that a dimensional measure of depressive symptomatology (e.g. the IDS-C) would have shown elevation at follow-up. We did find that excessive sleepiness predicted relapse into hypomania/mania, an association that has not received much attention in the literature. As mentioned above, this relationship did not appear to be attributable to medication administration. We also examined the prospective sleep of the excessive sleepiness group to see if they were sleeping *less*, as associations between decreased sleep and increased mania are established in the literature,⁸⁷ but did not find supportive evidence. There may be an as-yet unexplained biological marker contributing to both excessive sleepiness dysfunction and the circadian instability at the core of bipolar illness episodes.⁸⁸ Alternatively, a homeostatic regulatory process may underlie the relationship between excessive sleepiness in the euthymic period and reduced sleep need in hypomania/mania, though little is known about mechanisms of sleep regulation in either state.^{89,90}

The present findings should be considered in light of several important limitations. First, the study included only individuals with bipolar spectrum diagnoses given their strong relationship to hypersomnia; as such, results may lack generalizability to other psychiatric populations. Second, our findings were derived from a relatively small sample, though it was a sizeable sample to include clinician-administered interview and prospective sleep monitoring. Finally, we did not assess for medication changes or hypersomnia at follow-up assessment, so we are unable to comment on the chronicity of hypersomnia complaints or the impact of medication changes on mood episodes.

This present findings have implications for the newly-published DSM-V and set an agenda for future research. As currently stated, DSM-V criteria for hypersomnolence disorder (what was previously referred to as hypersomnia in the DSM-IV) hinge on “a complaint of excessive sleepiness” defined via excessive sleep drive, long sleep, or excessive sleep inertia. The present research clearly demonstrates that excessive sleepiness and long sleep are separate subgroups. As long as they remain together under the umbrella term hypersomnolence, excessive sleepiness and long sleep will continue to confuse the literature and impede generalizability. Future research that investigates characteristics and consequences of each group separately is needed to better understand hypersomnia, and both population-based and clinical investigations that utilize semi-structured interviews along with self report are useful in preventing sleep estimation bias. Additionally, treatment research is needed to identify interventions tailored for each subtype. For example, considering behavioral treatment options, interventions focusing on behavioral activation⁸² or social rhythms stabilization⁹¹ may be successful for long sleep, whereas interventions focused on light⁹² or minimizing sleep inertia⁹³ may differentially impact excessive sleepiness.

References

1. Roberts R, Roberts, C., Chen, I. Functioning of adolescents with symptoms of disturbed sleep. *J Youth Adolesc.* 2001;30:1-18.
2. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. *Biological Psychiatry.* 1996;39:411-418.
3. Gooneratne NS, Weaver TE, Cater JR, et al. Functional outcomes of excessive daytime sleepiness in older adults. *Journal of the American Geriatrics Society.* 2003;51:642-649.
4. Jennum P, Kjellberg J. The socio-economical burden of hypersomnia. *Acta Neurol Scand.* Apr 2010;121(4):265-270.
5. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. *Sleep.* May 2010;33(5):585-592.
6. Kaplan KA, Harvey AG. Hypersomnia across mood disorders: A review and synthesis. *Sleep Medicine Reviews.* 2009;13:275-285.
7. Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. *Arch Gen Psychiatry.* Aug 2003;60(8):817-826.
8. Iovieno N, van Nieuwenhuizen A, Clain A, Baer L, Nierenberg AA. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. *Depress Anxiety.* Feb 2011;28(2):137-144.
9. Worthington J, Fava M, Davidson K, Alpert JE, Nierenger A, Rosenbaum J. Patterns of improvement in depressive symptoms with fluoxetine treatment. *Psychopharmacological Bulletin.* 1995;31:223-226.
10. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N. Differences between minimally depressed patients who do and do not consider themselves to be in remission. *Journal of Clinical Psychiatry.* 2005;66:1134-1138.
11. Ford DE, Cooper-Patrick L. Sleep disturbances and mood disorders: an epidemiologic perspective. *Depress Anxiety.* 2001;14:3-6.
12. Kaplan KA, Gruber J, Eidelman P, Talbot LS, Harvey AG. Hypersomnia in inter-episode bipolar disorder: Does it have prognostic significance? *J Affect Disord.* Aug 2011;132(3):438-444.
13. Leibenluft E, Clark CH, Myers FS. The reproducibility of depressive and hypomanic symptoms across repeated episodes in patients with rapid-cycling bipolar disorder. *J Affect Disord.* Feb 21 1995;33(2):83-88.
14. Akiskal HS, Benazzi F. Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II? *J Affect Disord.* 2005;84:209-217.
15. Benazzi F. Symptoms of depression as possible markers of bipolar II disorder. *Prog Neuropsychopharmacol Biol Psychiatry.* May 2006;30(3):471-477.
16. Bowden CL. A different depression: clinical distinctions between bipolar and unipolar depression. *J Affect Disord.* 2005;84:117-125.
17. Billiard M, Dolenc L, Aldaz C, Ondze B, Besset A. Hypersomnia associated with mood disorders: a new perspective. *Journal of Psychosomatic Research.* 1994;38 Suppl 1:41-47.

18. Dolenc L, Besset A, Billiard M. Hypersomnia in association with dysthymia in comparison with idiopathic hypersomnia and normal controls. *Pflugers Arch*. 1996;431(6 Suppl 2):R303-304.
19. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders (4th Edition, Text revision)*. Washington, D.C.: American Psychiatric Association; 2000.
20. Williamson DE, Birmaher B, Brent DA, Balach L, Dahl RE, Ryan ND. Atypical symptoms of depression in a sample of depressed child and adolescent outpatients. *J Am Acad Child Adolesc Psychiatry*. Oct 2000;39(10):1253-1259.
21. Parker G, Malhi G, Hadzi-Pavlovic D, Parker K. Sleeping in? The impact of age and depressive sub-type on hypersomnia. *Journal of Affective Disorders*. Jan 2006;90(1):73-76.
22. Tam EM, Lam RW, Robertson HA, Stewart JN, Yatham LN, Zis AP. Atypical depressive symptoms in seasonal and non-seasonal mood disorders. *J Affect Disord*. Jun 1997;44(1):39-44.
23. Avery DH, Khan A, Dager SR, Cohen S, Cox GB, Dunner DL. Morning or evening bright light treatment of winter depression? The significance of hypersomnia. *Biol Psychiatry*. Jan 15 1991;29(2):117-126.
24. World Health Organization. *The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research*. Geneva, Switzerland: WHO; 1993.
25. American Academy of Sleep Medicine. *International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd Ed.* 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
26. Ohayon MM, Dauvilliers Y, Reynolds CF, 3rd. Operational definitions and algorithms for excessive sleepiness in the general population: implications for DSM-5 nosology. *Arch Gen Psychiatry*. Jan 2012;69(1):71-79.
27. Nofzinger EA, Thase ME, Reynolds 3rd CF, et al. Hypersomnia in bipolar depression: A comparison with narcolepsy using the multiple sleep latency test. *American Journal of Psychiatry*. 1991;148:1177-1181.
28. Vgontzas AN, Bixler EO, Kales A, Criley C, Vela-Bueno A. Differences in nocturnal and daytime sleep between primary and psychiatric hypersomnia: diagnostic and treatment implications. *Psychosom Med*. Mar-Apr 2000;62(2):220-226.
29. Harvey AG, Tang NK. (Mis)perception of sleep in insomnia: a puzzle and a resolution. *Psychol Bull*. Jan 2012;138(1):77-101.
30. Mercer JD, Bootzin RR, Lack LC. Insomniacs' perception of wake instead of sleep. *Sleep*. 2002;25:564-571.
31. Attarian HP, Duntley S, Brown KM. Reverse sleep state misperception. *Sleep medicine*. 2004;5:269-272.
32. Trajanovic NN, Radivojevic V, Kaushansky Y, Shapiro CM. Positive sleep state misperception - a new concept of sleep misperception. *Sleep Med*. Mar 2007;8(2):111-118.
33. Edinger JD, Bonnet MH, Bootzin RR, et al. Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. *Sleep*. 2004;27:1567-1596.
34. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): Psychometric properties. *Psychological Medicine*. 1996;26:477-486.
35. Young R, Biggs J, Ziegler V, Meyer D. A rating scale for mania: reliability, validity and sensitivity *British Journal of Psychiatry*. 1978;133:429-425.

36. Almeida JR, Akkal D, Hassel S, et al. Reduced gray matter volume in ventral prefrontal cortex but not amygdala in bipolar disorder: significant effects of gender and trait anxiety. *Psychiatry Res.* Jan 30 2009;171(1):54-68.
37. Phillips ML, Travis MJ, Fagiolini A, Kupfer DJ. Medication effects in neuroimaging studies of bipolar disorder. *American Journal of Psychiatry.* Mar 2008;165:313-320.
38. First MB, Spitzer RL, Gibbon M, Williams JBW. The structured clinical interview for DSM-III-R personality disorders (SCID-II): multi-site test-retest reliability study. *Journal of Personality Disorders.* 1995;9:92-104.
39. Skre I, Onstad S, Torgersen S, Kringlen E. High interrater reliability for the Structured Clinical Interview for DSM-III-R Axis I (SCID-I). *Acta Psychiatr Scand.* Aug 1991;84(2):167-173.
40. Williams JB, Gibbon M, First MB, et al. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. *Archives of General Psychiatry.* 1992;49(8):630-636.
41. Edinger JD, Wyatt, J. K., Olsen, M. K., Stechuchak, K. M., Carney, C. E., Chiang, A., et al. Reliability and validity of the Duke Structured Interview for Sleep Disorders for insomnia screening. 23rd Annual Meeting of the Associated Professional Sleep Societies, LLC; 2009.
42. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. *Psychological Medicine.* 2004;34:73-82.
43. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. *British Journal of Psychiatry.* 1978;133:429-435.
44. Plante DT, Landsness EC, Peterson MJ, et al. Altered slow wave activity in major depressive disorder with hypersomnia: a high density EEG pilot study. *Psychiatry Res.* Mar 31 2012;201(3):240-244.
45. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol Bull.* Mar 1979;86(2):420-428.
46. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. *Psychiatry Research.* 1989;28:193-213.
47. Carpenter JS, Andrykowski MA. Psychometric evaluation of the Pittsburgh Sleep Quality Index. *J Psychosom Res.* Jul 1998;45(1):5-13.
48. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep.* 1991;14:540-545.
49. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. *Sleep.* Aug 1992;15(4):376-381.
50. Gehrman P, Matt GE, Turingan M, Dinh Q, Ancoli-Israel S. Towards an understanding of self-reports of sleep. *Journal of Sleep Research.* 2002;11:229-236.
51. Morin CM, Espie CA. *Insomnia : a clinical guide to assessment and treatment.* New York: Kluwer Academic/Plenum Publishers; 2003.
52. Buysse D, Ancoli-Israel S, Edinger JD, Lichstein KL, Morin CM. Recommendations for a standard research assessment of insomnia. *Sleep.* 2006;29:1155-1173.
53. Carney CE, Buysse DJ, Ancoli-Israel S, et al. The consensus sleep diary: standardizing prospective sleep self-monitoring. *Sleep.* Feb 2012;35(2):287-302.

54. Lam DH, Watkins ER, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. *Archives of General Psychiatry*. 2003;60:145-152.
55. Jones SH, Hare DJ, Evershed K. Actigraphic assessment of circadian activity and sleep patterns in bipolar disorder. *Bipolar Disord*. 2005;7:176-186.
56. Harvey AG, Schmidt DA, Scarna A, Semler CN, Goodwin GM. Sleep-related functioning in euthymic patients with bipolar disorder, patients with insomnia, and subjects without sleep problems. *American Journal of Psychiatry*. 2005;162:50-57.
57. Millar A, Espie CA, Scott J. The sleep of remitted bipolar outpatients: A controlled naturalistic study using actigraphy. *Journal of Affective Disorders*. 2004;80:145-153.
58. Kaplan KA, Talbot LS, Gruber J, Harvey AG. Evaluating sleep in bipolar disorder: comparison between actigraphy, polysomnography, and sleep diary. *Bipolar Disord*. Dec 2012;14(8):870-879.
59. MacCallum RC, Widaman, K. F., Zhang, S., & Hong, S. Sample size in factor analysis. *Psychological Methods*. 1999;4(1):84-99.
60. Marsh HW, Balla, J. R., & McDonald, R. P. Goodness-of-fit indexes in confirmatory factor analysis: The effect of sample size. *Psychological bulletin*. 1988;103(3):391-410.
61. Hair JF, Anderson, R. E., Tatham, R. L., & Black, W. C. *Multivariate data analysis with readings*. 5th ed. Englewood Cliffs, NJ: Prentice-Hall; 1998.
62. Hu LT, & Bentler, P. M. Evaluating model fit. In: Hoyle RH, ed. *Structural equation modeling: Concepts, issues and applications*. Thousand Oaks, CA: Sage; 1995:76-99.
63. Cheung GW, & Rensvold, R. B. Evaluating goodness-of-fit indexes for testing measurement invariance. *Structural Equation Modeling: A Multidisciplinary Journal*. 2002;9(2):233-255.
64. Muthén B. *Latent variable analysis*. Thousand Oaks, CA: Sage Publications; 2004.
65. Hagenaars JA, McCutcheon AL, eds. *Applied Latent Class Analysis*. Cambridge: Cambridge University Press; 2002.
66. Muthén LK, & Muthén, B. O. *Mplus User's Guide*. Sixth ed. Los Angeles, CA 2007.
67. Nylund KL, Asparoutiov T, Muthen BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: A Monte Carlo simulation study. *Struct Equ Modeling*. 2007;14(4):535-569.
68. Lo Y, Mendell, N.R., & Rubin, D.B. Testing the number of components in a normal mixture. *Biometrika*. 2001;88:767-778.
69. McLachlan GJ, Peel, D. *Finite mixture models*. New York: John Wiley; 2000.
70. Philips ML, Travis MJ, Fagiolini A, Kupfer DJ. Medication effects in neuroimaging studies of bipolar disorder. *American Journal of Psychiatry*. 2008;165:313-320.
71. Sackeim HA. The definition and meaning of treatment-resistant depression. *J Clin Psychiatry*. 2001;62 Suppl 16:10-17.
72. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. *J Clin Psychopharmacol*. Apr 2004;24(2):192-208.
73. PDR Staff. *Physicians' Desk Reference 2008: Hospital/Library Version*. 62nd ed. Stamford: Thomson Healthcare; 2007.
74. Hu Lt, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. *Structural Equation Modeling: A Multidisciplinary Journal*. 1999;6(1):1-55.
75. Garrett ES, Eaton WW, Zeger S. Methods for evaluating the performance of diagnostic tests in the absence of a gold standard: a latent class model approach. *Statistics in medicine*. May 15 2002;21(9):1289-1307.

76. Ohayon MM, Reynolds CF, Dauvilliers Y. Excessive sleep duration and quality of life. *Annals of Neurology*. 2013.
77. GlaxoSmithKline. *Psychotropic Prescribing Guide (Physician's Desk Reference)*. Eighth ed. NY: Thompson PDR; 2005.
78. Staff P. Physicians' desk reference : PDR. 62nd ed. Oradell, N.J.: Medical Economics Co.; 2007.
79. Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. *J Clin Psychiatry*. 2008;69 Suppl 1:18-31.
80. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. *Postgraduate medicine*. Apr 2000;Spec No:1-104.
81. Aeschbach D, Sher L, Postolache TT, Matthews JR, Jackson MA, Wehr TA. A longer biological night in long sleepers than in short sleepers. *The Journal of clinical endocrinology and metabolism*. Jan 2003;88(1):26-30.
82. Jacobson N, Martell C, Dimidjian S. Behavioral activation treatment for depression: returning to contextual roots. *Clinical Psychology Science and Practice*. 2001;8:255-270.
83. Kanbayashi T, Kodama T, Kondo H, et al. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. *Sleep*. Feb 2009;32(2):181-187.
84. Goel N, Banks S, Mignot E, Dinges DF. DQB1*0602 predicts interindividual differences in physiologic sleep, sleepiness, and fatigue. *Neurology*. Oct 26 2010;75(17):1509-1519.
85. Morgenthaler T, Alessi C, Friedman L, et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. *Sleep*. Apr 2007;30(4):519-529.
86. Cho HJ, Lavretsky H, Olmstead R, Levin MJ, Oxman MN, Irwin MR. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. *The American journal of psychiatry*. Dec 2008;165(12):1543-1550.
87. Colombo C, Benedetti F, Barbini B, Campori E, Smeraldi E. Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. *Psychiatry Res*. Jun 30 1999;86(3):267-270.
88. Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. *The American journal of psychiatry*. Jul 2008;165(7):820-829.
89. Wehr TA, Sack DA, Rosenthal NE. Sleep reduction as a final common pathway in the genesis of mania. *The American journal of psychiatry*. Feb 1987;144(2):201-204.
90. Plante DT, Winkelman JW. Sleep disturbance in bipolar disorder: therapeutic implications. *The American journal of psychiatry*. Jul 2008;165(7):830-843.
91. Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. *Biol Psychiatry*. Sep 15 2000;48(6):593-604.
92. Kaida K, Takahashi M, Haratani T, Otsuka Y, Fukasawa K, Nakata A. Indoor exposure to natural bright light prevents afternoon sleepiness. *Sleep*. Apr 2006;29(4):462-469.
93. Hayashi M, Masuda A, Hori T. The alerting effects of caffeine, bright light and face washing after a short daytime nap. *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology*. Dec 2003;114(12):2268-2278.

Table 1. Participant characteristics.

Demographic Variable	N=159
Age, mean (SD)	35.8 (11.4)
Women, No. (%)	103 (65.6%)
Race/Ethnicity, No. (%)	
African American	13 (8.4%)
Asian American	20 (12.9%)
Caucasian	100 (64.5%)
Hispanic	10 (6.5%)
Other/Biracial	12 (7.8%)
Employment Status, No. (%)	
Full Time/Part Time	87 (56.9%)
Unemployed/Retired/Disability	66 (43.1%)
Marital Status, No. (%)	
Married/Partnered	33 (20.9%)
Separated/Divorced/Widowed	27 (17.1%)
Single	98 (62.0%)
Annual Income, No. (%)	
Less than \$50,000	95 (73.6%)
Greater than \$50,000	34 (26.4%)
IDS-C Total Score, mean (SD)	11.7 (7.6)
YMRS Total Score, mean (SD)	3.3 (2.9)
Psychotropic Medications, No. (%)	
None	10 (6.3%)
Monotherapy	35 (22.0%)
Polytherapy	114 (71.7%)
Mood Stabilizers/Anticonvulsants	96 (60.4%)
Antidepressants	85 (53.5%)
Atypical Antipsychotics	77 (48.4%)
Typical Antipsychotics	2 (1.3%)
Anxiolytics	36 (22.6%)
Stimulants	9 (5.7%)
Sleep/Hypnotics	37 (23.3%)

Table 2. CFA factor loadings and R² values, and LPA item response probabilities for the six selected indicators of hypersomnia.

Indicator	CFA			LPA			
	Factor 1	Factor 2	R ²	Class 1	Class 2	Class 3	Class 4
	'Long Sleep'	'Excessive Sleepiness'		'Long Sleep'	'Excessive Sleepiness'	'Short Sleep'	'Normal Sleep'
IDS-C Hypersomnia Item (0-3)	0.81	-	0.66	2.18	0.00	0.00	1.00
IDS-SR Hypersomnia Item (0-3)	0.74	-	0.54	2.15	1.88	0.22	1.25
PSQI Sleep Duration Item, in hours	0.67	-	0.44	9.22h	7.11h	6.39h	8.23h
Epworth Sleepiness Scale Total	-	0.81	0.66	6.57	12.17	6.77	6.78
PSQI Daytime Dysfunction Subscale Score	-	0.34	0.12	1.43	2.28	1.21	1.44
Excessive Sleepiness Item (0-4)	-	0.62	0.38	1.91	3.41	1.93	1.97

Note: CFA, confirmatory factor analysis; LPA, latent profile analysis, IDS-C, Inventory of Depressive Symptomatology, Clinician Rated Version; IDS-SR, Inventory of Depressive Symptomatology, Self-Report Version; PSQI, Pittsburgh Sleep Quality Index.